Artelo Biosciences, Inc. (ARTL)
- Previous Close
1.3800 - Open
1.3600 - Bid --
- Ask --
- Day's Range
1.3600 - 1.3600 - 52 Week Range
1.1500 - 2.9800 - Volume
238 - Avg. Volume
13,422 - Market Cap (intraday)
4.39M - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-3.1400 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
www.artelobio.comRecent News: ARTL
Performance Overview: ARTL
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARTL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARTL
Valuation Measures
Market Cap
4.30M
Enterprise Value
-6.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.37
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.09%
Return on Equity (ttm)
-59.63%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.29M
Diluted EPS (ttm)
-3.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
10.43M
Total Debt/Equity (mrq)
0.20%
Levered Free Cash Flow (ttm)
-4.64M
Research Analysis: ARTL
Company Insights: ARTL
ARTL does not have Company Insights